

Date	Journal	Title	Study type	Country	Authors	Link	Trial identifier	Intervention	Main question
28 September 2020	Lancet	Anti-CSa antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial	RCT	Netherlands	Alexander P J Vlaar, et al.	https://www.thelancet.com/action/showPdf?pii=S2665-9913%2820%2930341-6	NCT04333420	Vilobelimab	Phase 2 study to explore the potential benefit and safety of IFX-1 (vilobelimab) in patients with severe COVID-19.
29 September 2020	NEJM	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults	Vaccine trial Phase 1	USA	Evan J. Anderson, et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2028436	NCT04283461	mRNA-1273 vaccine	Is the SARS CoV-2 mRNA 1273 safe and well tolerated in older adults and does it elicit an immune response?
30 September 2020 -pre-approved	Nature	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses	Vaccine trial Phase 1 and 2	Germany	Ugur Sahin, et al.	https://www.nature.com/articles/s41586-020-2814-7	NCT04380701	BNT162b1 vaccine	Does the BNT162b1 vaccine elicit both antibody and T-cell response in healthy adults?
Preprint	Research Square	Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients	RCT	China	Chuan Li, et al.	https://assets.researchsquare.com/files/rs-65224/v1/22886bf0-ce06-4d42-aeb6-c73ebb7c2003.pdf	ChiCTR2000029638	Engineered interferon alpha	To evaluate the efficacy and safety of recombinant super-compound interferon versus traditional interferon alpha in patients with moderate to severe COVID-19
24 August 2020	International Immunopharmacology	Interferon β -1b in treatment of severe COVID-19: A randomized clinical trial	RCT	Iran	Hamid Rahmani, et al.	https://www.sciencedirect.com/science/article/pii/S1567576920323304?via%3DIihub	IRCT20100228003449N27	Interferon β -1b	To evaluate the efficacy and safety of interferon (IFN) β -1b in the treatment of patients with severe COVID-19

30 September 2020	JAMA	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers	RCT	USA	Benjamin S Abella, et al.	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771265	NCT04329923	Hydroxychloroquine	To evaluate the efficacy of hydroxychloroquine to prevent transmission of SARS-CoV-2 in hospital-based HCWs with exposure to patients with COVID-19 using a pre-exposure prophylaxis strategy
4 September 2020	BMJ	Drug treatments for covid-19: living systematic review and network meta-analysis	Systematic review	International collaboration	Reed AC Siemieniuk, et al.	https://www.bmj.com/content/370/bmj.m2980	NA	All treatments	To compare the effects of treatments for coronavirus disease 2019 (covid-19).
15-oct	Virus Research	Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials	Meta-analysis	USA, Japan	Yokoyama et al.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437510/pdf/main.pdf	N/A	Remdesivir	To compare the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care.
06-sept	MedRxiv	An in-depth investigation of the safety and immunogenicity of an inactivated 2 SARS-CoV-2 vaccine	Phase 1 RCT	China	Pu et al.	https://www.medrxiv.org/content/10.1101/2020.09.27.20189548v1.full.pdf	NCT04412538	Vaccine	To investigate the safety and immunogenicity of an inactivated viral vaccine in immunized individuals in a phase I trial, especially focusing on safety with regard to the immunopathology of the vaccine.
11-oct	MedRxiv	Clearing the fog: Is Hydroxychloroquine effective in reducing Corona virus disease-2019 progression: A randomized controlled trial	RCT	Pakistan	Mehmood Kamran et al.	https://www.medrxiv.org/content/10.1101/2020.07.30.20165365v2.full.pdf	NCT04491994	Hydroxychloroquine	To assess the efficacy of HCQ in reducing disease progression in mild COVID 19
05-oct-20	The Lancet	Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	RCT	UK	Horby et al. (RECOVERY GROUP)	https://www.thelancet.com/action/showPdf?pii=S0140-6736(20)32932013-4	ISRCTN 50189673, NCT04381936	lopinavir/ritonavir	Whether lopinavir–ritonavir improves outcomes in patients admitted to hospital with COVID-19
20-sept-20	EClinicalMedicine	An open-label, randomized trial of the combination of IFN-kappa plus TFF2 with standard care in the treatment of patients with moderate COVID-19	RCT	China	Fu et al.	https://www.sciencedirect.com/science/article/pii/S2589537020302911?via%3DIhuh	ChiCTR2000030262	IFN- κ , TFF2	Efficacy and safety of IFN- κ and TFF2 in COVID patients.

25-sept	MedRxiv	Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial	Phase 1/2a RCT	Netherlands, Belgium, USA	Sadoff et al.	https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1.full.pdf	NCT04436276	Vaccine: non-replicating adenovirus 26 based vector expressing the stabilized pre-fusion spike protein of SARS-CoV-2	To evaluate the efficacy of a single vaccination of 5x10 ¹⁰ vp of Ad26.COV2.S
21-sept	MedRxiv	Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial	RCT	USA	Rajasingham et al.	https://www.medrxiv.org/content/10.1101/2020.09.18.20197327v1.full.pdf	NCT04328467	Hydroxychloroquine	To determine the effectiveness of hydroxychloroquine as pre-exposure prophylaxis in healthcare workers at high-risk of SARS-CoV-2 exposure
22-sept	MedRxiv	Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and 4 Controlled Clinical Trial	RCT	Cuba	Cruz et al.	https://www.medrxiv.org/content/10.1101/2020.09.03.20187112v2.full.pdf	IG/CIGB3001/CV/2001, ATENEA-Co-300 trial	Anti-CK2 Synthetic Peptide, CIGB-325	To explore safety and efficacy of CIGB-325, an anti-CK2 peptide, in COVID-19 patients.
15-oct	Virus Research	Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials	Meta-analysis	USA, Japan	Yujiro Yokoyama et al.	https://www.sciencedirect.com/science/article/pii/S0168170220310443?via%3Dihub	N/A	Remdesivir	To compare the rate of clinical improvement among patients with COVID-19 who received 5-day course of remdesivir versus 10-day course of remdesivir versus standard care.
24 July 2020	Clinical Infectious Diseases	Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care	RCT vs cohort	USA	Susan A. Olander et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1041/5876045	NCT04292899 and EUPAS34303	Remdesivir	Efficacy of remdesivir in COVID19 patients

Preprint	Antimicrobial Agents Chemotherapy	A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19	RCT	Japan	Yohei Doi, et al.	https://aac.asm.org/content/early/2020/09/16/AAC.01897-20	jRCTs041190120	Favipiravir	Assess the efficacy of favipiravir in asymptomatic or mild COVID19 patients in viral clearance, and resolution of symptoms
24-sept	Virology Journal	Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis	Systematic review & meta-analysis	Nepal	Dhan Bahadur Shrestha et al.	https://virology.biomedcentral.com/articles/10.1186/s12985-020-01412-z	N/A	Favipiravir	To evaluate the efficacy and safety of the drug Favipiravir as a treatment for COVID-19.
20 September 2020	Thrombosis Research	Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)	RCT	Brazil	Anna Cristina Bertoldi Lemos, et al.	https://www.thrombosisresearch.com/article/S0049-3848(20)30530-2/fulltext#%20	REBEC RBR-949z6v	Enoxaparin, anticoagulants	To compare therapeutic enoxaparin treatment to standard prophylactic anticoagulant treatment in severe COVID19
Preprint	Clinical Infectious Diseases	Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Lefunomide -- a Single-Center, Randomized, Controlled Clinical Trial	RCT	China	Wang, et al	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/cia1417/5909448	ChiCTR 2000030058	Lefunomide	To evaluate the efficacy and safety of leflunomide to treat COVID-19 patients with prolonged post-symptomatic viral shedding.
26 August 2020	Clinical Microbiology and Infection	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis	Systematic Review and Meta-analysis	France, Switzerland	Thibault Fiolet, et al.	https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30505-X/fulltext	NA	Chloroquine, hydroxychloroquine, azithromycin	To assess the effect of chloroquine and hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients
Preprint	MedRxiv	Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: Randomized Control Trial in Singapore	RCT	Singapore	Chaminda Jayampath Seneviratne, et al.	https://www.medrxiv.org/content/10.1101/2020.09.14.20186494v1	NA	Mouth wash	To evaluate and compare different commercial mouthwash solutions and their effect on reducing salivary viral load

Preprint	MedRxiv	Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial	RCT	Chile	Maria Elvira Balcells, et al.	https://www.medrxiv.org/content/10.1101/2020.09.17.20196212v1	NCT04375098	Convalescent Plasma	Evaluate the safety and efficacy of convalescent plasma and compare an early vs deferred treatment strategy
19 July 2020	Bioimpacts	Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial	RCT	Iran	Khalil Ansarin	https://bi.tbzmed.ac.ir/article/bi-23240	IRCT202003117046797N4	Bromhexine	Evaluate the efficacy of bromhexine in intensive care unit (ICU) admission, mechanical ventilation, and mortality in patients with COVID-19.
12-sept-20	Expert Review of Anti-Infective Therapy	The effect of antivirals on COVID-19: a systematic review	Systematic review	Hussain et al.	UK	https://www.tandfonline.com/doi/abs/10.1080/14787210.2021.1823832?journalCode=ier20	NA	Antivirals	Identify studies pertaining to antivirals in COVID-19 patients and review the clinical outcomes
23 September 2020	Clinical Infectious Diseases	Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19	RCT	Brazil	Julio Cesar Garcia de Alencar, et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1443/5910353			To determine whether NAC in high doses can avoid respiratory failure in patients with Covid-19.
17-sept-20	European Respiratory Journal	Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial	RCT	Iran	Edalatifard et al.	https://erj.ersjournals.com/content/early/2020/09/09/13993003.02808-2020	IRCT20200404046947N1	Methylprednisolone	Is methylprednisolone effective in treatment of COVID-19 patients?
17-sept-20	Plos Medicine	Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)	Meta-analysis	Denmark	Juul et al.	https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003293	NA	NA	Effects of all treatment interventions for COVID-19

04-sept-20	The Lancet	Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia	CT	Russia	Logunov et al.	https://www.sciencedirect.com/science/article/pii/S0140673620318663?via%3Dihub	NCT04436471 and NCT04437875	vaccine	Safety and immunogenicity of two formulations (frozen and lyophilised) of vaccine
01-oct-20	International Journal of Antimicrobial Agents	Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial	RCT	Iran	Sekhavati et al.	https://www.sciencedirect.com/science/article/pii/S0924857920303411?via%3Dihub	NA	azithromycin	Can therapy with HCQ+AZM reduce the hospital length of stay in COVID-19 patients?
10-sept-20	JAMA	Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial	RCT	China	Cheng et al.	https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2770680	ChiCTR2000030007	G-CSF	Do increased peripheral blood leukocyte and lymphocyte cell counts lead to clinical improvement in patients with COVID-19?
04-sept-20	The Lancet	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial	RCT	Brazil	Furtado et al.	https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931862-6	NCT04321278	azithromycin	Would azithromycin improve clinical outcomes to COVID-19 patients?
03-sept-20	Journal General Internal Medicine	Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis	Systematic review	India	Arunmozhimaran Elavarasi, et al.	https://link.springer.com/article/10.1007/s11606-020-06146-w	NA	Chloroquine, hydroxychloroquine	Is the use of CQ or HCQ effective and safe in reducing mortality and improving the clinical course, fever remission, and virologic clearance in COVID-19 patients?
November - December 2020	Diabetes & Metabolic Syndrome: Clinical Research & Reviews	No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials"	Systematic review	India	Pathak et al.	https://www.sciencedirect.com/science/article/pii/S1871402120303362?via%3Dihub	NA	hydroxychloroquine	Is HCQ effective in mild to moderate COVID-19 patients?

06-sept-20	Naunyn-Schmiedeberg's Archives of Pharmacology	Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis	Systematic review	China	Zang et al	https://link.springer.com/article/10.1007%2F5002-10-020-01964-5	NA	hydroxychloroquine	Benefits and harms of HCQ in COVID-19 patients
02-sept-20	JAMA	Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial	RCT	Brazil	Bruno M. Tomazini, et al.	https://jamanetwork.com/journals/jama/fullarticle/2770277?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.17021	NCT04327401	Dexamethasone	To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19-associated ARDS.
02-sept-20	JAMA	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 - A Meta-analysis	Meta-analysis	International Collaboration	Jonathan A.C., et al.	https://jamanetwork.com/journals/jama/fullarticle/2770279?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.17023	PROSPERO database (CRD42020197242)	Corticosteroids	To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality.
02-sept-20	JAMA	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 - A Randomized Clinical Trial	RCT	France	Pierre-François Dequin, et al.	https://jamanetwork.com/journals/jama/fullarticle/2770276?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.16761	NCT02517489	Hydrocortisone	Does low-dose hydrocortisone decrease treatment failure in patients with COVID-19-related acute respiratory failure?
02-sept-20	JAMA	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial	RCT	UK	Derek C. Angus, et al.	https://jamanetwork.com/journals/jama/fullarticle/2770278?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jama.2020.17022	NCT02735707	Hydrocortisone	To determine whether hydrocortisone improves outcome for patients with severe COVID-19.
08-sept	MedRxiv	Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)	RCT	India	Anup Agarwal et al. and PLACID Collaborators	https://www.medrxiv.org/content/10.1101/2020.09.03.20187252v1.full.pdf	CTRI/2020/04/024775	Convalescent plasma	To assess the effectiveness of Convalescent plasma for the treatment of COVID-19
01-sept	MedRxiv	Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial	RCT	Spain	Avendaño-Solà et al.	https://www.medrxiv.org/content/10.1101/2020.08.26.20182444v3.full.pdf	NCT04345523	Convalescent plasma	To demonstrate the efficacy and safety of Convalescent Plasma used to prevent progression to severe disease or death in hospitalized patients with earlier forms of COVID-19

09-sept	MedRxiv	Early viral clearance among COVID-19 patients when gargling with Povidone-iodine and Essential oils - a clinical trial.	RCT	Malaysia	Nurul Azmawati Mohamed et al.	https://www.medrxiv.org/content/10.1101/2020.09.07.20180448v1.full.pdf	NCT04410159	Gargling with 1% povidone-iodine (Betadine®), essential oils (Listerine®) or tap water	To assess the ability of regular gargling to eliminate SARS-CoV-2 in the oropharynx and nasopharynx.
12/09/2020	MedRxiv	Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia	RCT	USA	Rosas et al.	https://www.medrxiv.org/content/10.1101/2020.08.27.20183442v2.full.pdf	NCT04320615	Tocilizumab	To investigate whether tocilizumab has clinical benefit in hospitalized patients with severe COVID-19 pneumonia.
08-sept	Engineering	Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial	RCT	China	Wu et al.	https://www.sciencedirect.com/science/article/pii/S2095809920302411?via%3DIh	ChiCTR2000030001	Triazavirin	To assess the efficacy of Triazavirin (TZV) for Covid-19
10-sept	BMC Infectious Diseases.	Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical care alone: A Randomized, Open-Label, Controlled Trial.	RCT	Cuba	Delgado-Enciso et al.	https://assets.researchsquare.com/files/rs-68403/v1/e14a5067-cd36-4094-9c29-4bb66ac46805.pdf	RPCEC00000309	neutral electrolyzed saline	To evaluate the efficacy of treatment with intravenous and/or nebulized neutral electrolyzed saline combined with usual medical care versus usual medical care alone, in ambulatory patients with COVID-19.
01-sept-20	Computers in Biology and Medicine	Prediction of respiratory decompensation in Covid-19 patients using machine learning: The READY trial	RCT	USA	Burdick et al.	https://www.sciencedirect.com/science/article/pii/S0010482520302845?via%3DIh	NCT04390516	NA	NA
19-aout-20	Journal of Medical Virology	Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis	Review	China	Jiang et al.	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26443	NA	Remdesivir	Remdesivir and its clinical effect
19-aout-20	Journal of Antimicrobial Chemotherapy	Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial	RCT	Iran	Sadeghi et al.	https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa334/5889948	IRCT20200128046294N2	sofosbuvir/daclatasvir	IS sofosbuvir and dalatasvir effective in COVID patients?

18-août-20	Stem Cell Research & Therapy	Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells	RCT	China	Shu et al.	https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01875-5	ChiCTR2000031494	umbilical cord mesenchymal stem cells	Are human umbilical cord mesenchymal stem cell infusion effective and safe for the treatment of severe COVID?
October	Journal of Steroid Biochemistry and Molecular Biology	"Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study	RCT	Spain	Marta Entrenas Castillo, et al.	https://www.sciencedirect.com/science/article/pii/S0960076020302764?via%3Dihub	NCT04366908	Calcifediol	Evaluate the effect of calcifediol on ICU admission and mortality among patients hospitalized for COVID-19
13 August 2020	JAMA	Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials	Vaccine - Phase I and II	China	Shengli Xia, et al.	https://jamanetwork.com/journals/jama/fullarticle/2769612	ChiCTR2000031809	Inactivated vaccine	To assess the safety and immunogenicity of this whole virus inactivated vaccine
21 August 2020	JAMA	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19	RCT	USA	Christoph D. Spinner, et al.	https://jamanetwork.com/journals/jama/fullarticle/2769871	NCT04292730	Remdesivir	Effect of remdesivir in patients with moderate COVID19
30 July 2020	BMJ	Drug treatments for covid-19: living systematic review and network meta-analysis	Systematic Review	International Collaboration	Reed AC Siemieniuk, et al.	https://www.bmj.com/content/370/bmj.m2980	NA	All treatments	Living systematic review and network meta-analysis

28-août	MedRxiv	RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study	RCT	USA/ Germany	Walsh et al.	https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v2.full.pdf	NCT04368728	Vaccine: RNA vaccines BNT162b1 and BNT162b2	To assess the safety and immunogenicity of varying dose levels of vaccines BNT162b1 and BNT162b2.
12 August 2020	Clinical Infectious Diseases	Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial	RCT	Brazil	Christiane Maria Prado Jeronimo, et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1177/5891816	NCT04343729	Methylprednisolone	Assess the efficacy of short-term methylprednisolone in patients with COVID-19
09 August 2020	Clinical Infectious Diseases	AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial	RCT	Russia	Andrey A. Ivashchenko, et al.	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1176/5890024	NCT04434248	Favipiravir	Assess the efficacy and safety of favipiravir in moderate COVID19 and select the optimal dosing regimen for further evaluation (Phase III).
Preprint	International Journal of Infectious Diseases	SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial		China	Fang Zheng, et al.	https://www.sciencedirect.com/science/article/pii/S120197122030597X?via%3DIihub	ChiCTR2000029496	Novaferon	Efficacy of Novaferon and Novaferon + Lopinavir/ritonavir in moderate and severe COVID19.
Preprint	medRxiv	Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report.	RCT	Argentina	Mariano Duarte, et al.	https://www.medrxiv.org/content/10.1101/2020.08.04.20167205v2	NCT04355936	Telmisartan	Assess the anti-inflammatory effect of telmisartan in COVID-19 patients

14 August 2020	Critical Care	Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial	RCT	USA	Joseph Miller, et al.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03220-x	NCT04345614.	Auxora	Safety and tolerability of auxora in severe or critical COVID-19
Preprint	medRxiv	Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial	Phase II vaccine RCT	China	YanJun Zhang, et al.	https://www.medrxiv.org/content/10.1101/2020.07.31.20161216v1	NCT04352608	Inactivated Vaccine	Is this SARS CoV 2 inactivated vaccine safe and well tolerated?
Preprint	medRxiv	Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial	RCT	Brazil	Maria IF Lopes, et al.	https://www.medrxiv.org/content/10.1101/2020.08.06.20169573v2	RBR-8jyhxh	Colchicine	To evaluate the efficacy of colchicine in treating severe and moderate COVID-19
2 September 2020	NEJM	Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine	Phase I vaccine RCT	Australia	Cheryl Keech, et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2026920	NCT04368988	NVX-CoV2373; recombinant nanoparticle vaccine	Assess the safety and tolerability of the NVX-CoV2373 recombinant vaccine in healthy subjects.
23 July 2020	NEMJ	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19	RCT	Brazil	Alexandre B. Cavalcanti, et al.	https://www.nejm.org/doi/10.1056/NEJMoa2019014	NCT04322123	Hydroxychloroquine	Asses the efficacy of hydroxychloroquine with and without azithromycin in mild to moderate COVID19
6 July 2020	Journal of Medical Virology	Systematic Review and Meta-analysis of Effectiveness of Treatment Options Against SARS-CoV-2 infection	Systematic review	USA	Viveksandeeep Thoguluva Chandrasekar, et al.	https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.26302	NA	Hydroxychloroquine, Tocilizumab, Remdesivir, convalescent plasma, steroids, lopinavir/ritonavir	Asses overall efficacy of treatments that have been studied thus far.

Preprint	medRxiv	Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19	CT	Cuba	Yayquier Díaz, et al.	https://www.medrxiv.org/content/10.1101/2020.07.24.20153833v1	RPCEC00000311	Itolizumab	Is itolizumab a safe and efficient treatment for COVID 19 in elderly patients?
Preprint	medRxiv	Efficacy and tolerability of bevacizumab in patients with severe Covid -19	CT	China, Italy	Jiaojiao Pang, et al	https://www.medrxiv.org/content/10.1101/2020.07.26.20159756v1	NCT04275414	Bevacizumab	Is bevacizumab a safe and efficient treatment for severe COVID 19?
29 July 2020	EClinicalMedicine (Lancet)	A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN- κ plus TFF2 in patients with moderate COVID-19	CT	China + USA	Weihui et al.	https://www.sciencedirect.com/science/article/pii/S2589537020302224	ChiCTR2000030262	IFN- κ plus trefoil factor 2	To evaluate the efficacy and safety of intranasal inhalation of TFF2 and IFN- κ protein for SARS-CoV-2 infection
21 July 2020	Virologica Sinica	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial	CT	China	Hu et al.	https://link.springer.com/article/10.1007%2Fs12250-020-00258-7	ChiCTR 2000030058	leflunomide	Is leflunomide effective in COVID-19 patients?
20-juil	Lancet	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial	RCT	UK	Folegatti et al. on behalf of the Oxford COVID Vaccine Trial Group	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext	ISRCTN 15281137; NCT04324606	ChAdOx1 nCoV-19 vaccine	To assess the immunogenicity, reactogenicity, and safety of vaccination with ChAdOx1 nCoV-19 in single-dose and two-dose regimens.
20-juil	Lancet	Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial	RCT	China	Feng-Cai Zhu et al.	https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931605-6	NCT04341389	adenovirus type-5 (Ad5)-vectored COVID-19 vaccine	Phase 2 trial to further evaluate the immunogenicity and safety in a larger population, and to determine an appropriate dose for the efficacy study

12 August 2020	Nature	Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults	Phase 1/2 trial	USA/Germany	Mulligan et al.	https://www.nature.com/articles/s41586-020-2639-4	NCT04368728	RNA Vaccine BNT162b1	To assess safety, tolerability, and immunogenicity of RNA Vaccine candidate in a dose escalation study among healthy adults.
20-juil-20	Medrxiv	Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine	Phase 1/2 trial	Germany/USA	Sahin et al.	https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1.full.pdf	NCT04380701, EudraCT: 2020-001038-36	RNA Vaccine BNT162b1	To complement previous reported data by providing a detailed characterisation of antibody and T76 cell immune responses elicited by BNT162b1 vaccination.
14-juil	NEMJ	An mRNA Vaccine against SARS-CoV-2 — Preliminary Report	Phase 1 trial	USA	Jackson et al.	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022483	NCT04283461	mRNA-1273 vaccine	To evaluate the safety and immunogenicity of mRNA-1273 vaccine
08-oct	NEJM	Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multicentre, randomized, controlled trial.	RCT	UK	Horby et al. (RECOVERY Collaborative Group)	https://www.nejm.org/doi/10.1056/NEJMoa2022926	ISRCTN 50189673, NCT04381936	Hydroxychloroquine	To assess the safety and efficacy of hydroxychloroquine in patients hospitalized with COVID-19
10-juil	Medrxiv	A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19)	RCT & retrospective cohort study	Taiwan	Cheng-Pin Chen et al.	https://www.medrxiv.org/content/10.1101/2020.07.08.20148841v1.full.pdf	NCT04384380	Hydroxychloroquine	To evaluate HCQ efficacy and tolerability in adult patients with mild to moderate COVID-19.
16-juil	Annals of Internal Medicine	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 - A Randomized Trial	RCT	USA	Skipper et al.	https://www.acpjournals.org/doi/10.7326/M20-4207	NCT04308668	Hydroxychloroquine	To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients

Preprint	Lancet	Hydroxychloroquine Alone or in Combination with Cobicistat-Boosted Darunavir for Treatment of Mild COVID-19: A Cluster-Randomized Clinical Trial	RTC	Spain	Mitjà et al,	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3615997	NCT04304053	Hydroxychloroquine, Darunavir, Cobicistat	Is early treatment with hydroxychloroquine (HCQ) with or without cobicistat/darunavir more efficacious than no-treatment for outpatients with mild Covid-19?
Preprint	ResearchSquare	A pragmatic randomized controlled trial reports the efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics	RCT	Norway	Magnus Nakrem Lyngbakken, et al.	https://assets.researchsquare.com/files/rs-44055/v1/3fb11155-d83c-48a0-ae74-b3cce9a5eac3.pdf	NCT04316377	Hydroxychloroquine	To assess the efficacy and safety of hydroxychloroquine therapy on SARS-CoV-2 oropharyngeal viral kinetics in patients hospitalized with moderately severe COVID-19.
11 June 2020	Open Forum Infectious Diseases	Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19	RCT	China	Jun Chen, et al.	https://pubmed.ncbi.nlm.nih.gov/32671131/	NCT04252274	Darunavir, Cobicistat	Evaluate the antiviral activity and safety of darunavir/cobicistat (DRV/c) for treating mild COVID-19
15-juil-20	SN Comprehensive Clinical Medicine	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials	Systematic review & Meta-analysis	USA	Juan A. Sioridia Jr et al.	https://link.springer.com/article/10.1007%2F2Fs42399-020-00399-6	N/A	lopinavir/ritonavir; arbidol; hydroxychloroquine; remdesivir; tocilizumab; favipiravir; heparin; dexamethasone	To assess the current evidence regarding human controlled COVID-19 treatment trials.
Preprint	BMC Infectious Diseases	A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients.	RT	Bangladesh	Abu Taiub Mohammed Mohiuddin Chowdhury, et al.	https://www.researchgate.net/profile/Abu_Taiub_Mohammed_Mohiuddin_Chowdhury2/publication/342159343_A_comparative_observational_study_on_Ivermectin-Doxycycline_and_Hydroxychloroquine-Azithromycin_therapy_on_COVID19_patients/links/5f02954c92851c52d619d95e/A-comparative-observational-study-on-Ivermectin-Doxycycline-and-Hydroxychloroquine-Azithromycin-therapy-on-COVID19-patients.pdf	NCT04434144	Ivermectin, Doxycycline, Hydroxychloroquine, Azithromycin	Compared outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy COVID19 patients with mild to moderate disease.
updated 12/10/20	Cochrane	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review	Systematic review	International Collaboration	Piechotta V, et al.	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub2/abstract	NA	Convalescent plasma, hyperimmune immunoglobulin	Assess the effectiveness of convalescent plasma and hyperimmune immunoglobulin for treating people with COVID19

Preprint	Advanced Science	A Randomized, Open-label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, A Pilot Study	RCT	China	Zhigang Ren, et al.	https://onlinelibrary.wiley.com/doi/epdf/10.1002/advs.202001435	ChiCTR2000029853	Azvudine	Efficacy of azvudine in treating mild COVID19 patients
24/06/2020	JAMA Network Open: Infectious Diseases	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019The GRECCO-19 Randomized Clinical Trial	Randomized clinical trial	Greece	Deftereos et al.	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767593	NCT04326790	Colchicine	To evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with COVID-19.
30-juin-20	The International Journal of Clinical Practice	Febuxostat Therapy in Outpatients With Suspected COVID-19: A Clinical Trial	RCT	Iran	Davoodi et al.	https://pubmed.ncbi.nlm.nih.gov/32603531/	IRCT2019072704434N1	Hydroxychloroquine, febuxostat	Is febuxostat effective in comparison with hydroxychloroquine?
17 July 2020	NEMJ	Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report	RCT	UK	Horby et al. (RECOVERY Writing Committee)	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021436?casa_token=H8GAcaEgprUAAAAA:m_9Qlb5FCP6d6YPLMryKLgVPOQTUouiqsD39ki_1j8u1svZDvAE7pLjZ3GbCpQSV4V62JZ8086BodT	ISRCTN 50189673, NCT04381936	Dexamethasone	To test the effectiveness of dexamethasone in patients hospitalized with COVID-19
18-juin	medRxiv	GLUCOCVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia	RCT	Spain	Corral-Gudino et al.	https://www.medrxiv.org/content/10.1101/2020.06.17.20133579v1.full.pdf	EudraCT number: 2020-001934-37	methylprednisolone	To determine whether a 6 day course of intravenous methylprednisolone (MP) improves outcome in patients with SARS CoV-2 infection at risk of developing Acute Respiratory Distress Syndrome (ARDS)
05-juin-20	Science Immunology	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19	RCT	USA	Roschewski et al.	https://immunology.sciencemag.org/content/5/48/eabd0110	NA	Acalabrutinib	Is acalabrutinib effective in severe COVID-19 patients?

8 June 2020 - Accelerated publication	Nature	Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe	Modelling	UK	Seth Flaxman, et al.	https://www.nature.com/articles/s41586-020-2405-7	NA	Non-pharmaceutical interventions	Were the non-pharmaceutical interventions implemented in European countries effective in limiting the spread of SARS CoV-2?
8 May 2020	Nature - Leukemia	The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation	Retrospective analysis	Germany	F. La Rosée, et al.	https://www.nature.com/articles/s41375-020-0891-0		Ruxolitinib	Efficacy and safety of ruxolitinib in severe COVID19
8 June 2020	Lancet Rheumatology	Canakinumab in a subgroup of patients with COVID-19	Retrospective analysis	Italy	Claudio Ucciferri, et al.	https://www.sciencedirect.com/science/article/pii/S2665991320301673?via%3Dihub	NA	Canakinumab	Is canakinumab a safe and effective treatment against COVID19?
10-juin-20	BMJ	Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study	Observational study	China	Min Liu et al.	https://www.bmj.com/content/369/bmj.m2195	NA	NA	To examine the protective effects of appropriate personal protective equipment
02-juin-20	The Lancet Digital Health	Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study	Modelling study	UK	Gavines et al.	https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30133-X/fulltext#%20	NA	NA	What is the impact of different control measures for mitigating the burden of COVID-19
01-juin-20	Journal of Clinical Microbiology	Clinical performance of the Luminex NxTAG CoV Extended Panel for SARS-CoV-2 detection in nasopharyngeal specimens of COVID-19 patients in Hong Kong	Diagnostic	Hong-Kong	Jonathan Hon-Kwan Chen	https://jcm.asm.org/content/early/2020/05/29/JCM.00936-20	NA	Nucleic acid test	Evaluation of Luminex NxTAG in COVID-19 detection

26-mai-20	Clinical Microbiology and Infection	Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review	Systematic review / Meta-analysis	Australia/Sri Lanka	Rodrigo et al.	https://www.sciencedirect.com/science/article/pii/S1198743X20302937?via%3Dihub	NA	Hydroxychloroquine, chloroquine	Does hydroxychloroquine have antiviral effect?
14-juin	MedRxiv	Kinetics of the humoral immune response to SARS-CoV-2: comparative analytical performance of seven commercial serology tests	Diagnostic	Belgium	Herroelen et al.	https://www.medrxiv.org/content/10.1101/2020.06.09.20124719v2.full.pdf	N/A	Antibody test	To test the performance characteristics of seven commercially available serology tests for detection of antibodies against the SARS-CoV-2
09-juin	MedRxiv	Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience	observational study	Cuba	Pereda et al.	https://www.medrxiv.org/content/10.1101/2020.05.29.20124619v1.full.pdf	RPCEC00000318	Interferon alpha 2b	To assess the therapeutic efficacy of IFN-α2b in patients infected with SARS-CoV-2
10-juin	MedRxiv	ICON (Ivermectin in COVID Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19	Retrospective analysis	USA	Cepelowicz Rajter et al.	https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2.full.pdf	N/A	Ivermectin	To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19
14-juin	MedRxiv	First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia	prospective study with FDA emergency use IND	USA	Temesgen et al.	https://www.medrxiv.org/content/10.1101/2020.06.08.20125369v2.full.pdf	N/A	Lenzilumab	To assess the efficacy of lenzilumab therapy in patients hospitalized with severe COVID-19 pneumonia, who had clinical and/or biomarker evidence for increased risk of progression to respiratory failure.
02-juin	MedRxiv	Low levels of the prognostic biomarker suPAR are predictive of mild outcome in patients with symptoms of COVID-19 - a prospective cohort study	prospective cohort study	Denmark/USA	Eugen-Olsen et al.	https://www.medrxiv.org/content/10.1101/2020.05.27.20114678v1.full.pdf	N/A	Prognostic biomarker	To investigate whether soluble urokinase plasminogen activator receptor (suPAR) can aid in identifying patients with low risk of respiratory failure when presenting with symptoms of COVID-19.
08/06/2020	MedRxiv	Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day-7 Interim Analysis of a Registered Clinical Trial	CT	USA	Hess et al.	https://www.medrxiv.org/content/10.1101/2020.06.03.20116988v1.full.pdf	NCT: 04366791	Low dose radiation	To determine if Low Dose Radiation Therapy can reduce pulmonary inflammation associated with COVID-19 pneumonia.
02-juin	MedRxiv	Efficacy and Safety of	CT	China	Wang et al.	https://www.medrxiv.org	ChiCTR2000030	Leflunomide	To evaluate the safety

08-juin	MedRxiv	Nano short peptide nutrition intervention on the prognosis of patients with COVID-19	Retrospective analysis	China	Zhang et al.	https://www.medrxiv.org/content/10.1101/2020.06.03.20083980v1.full.pdf	N/A	enteral nutrition	To explore the effect of high fiber whey short peptide enteral nutrition on the prognosis of patients with COVID-19
05-juin	MedRxiv	Ozone therapy for patients with SARS-COV-2 pneumonia: a single-center prospective cohort study	prospective cohort study	Spain/USA/Canada	Hernández et al.	https://www.medrxiv.org/content/10.1101/2020.06.03.20117994v1.full.pdf	N/A	Ozone therapy	To determine if ozonated autohemotherapy is associated with a shorter time to clinical improvement in patients with severe COVID-19 pneumonia.
02-juin	MedRxiv	CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patients	CT	Cuba	Venegas-Rodriguez et al.	https://www.medrxiv.org/content/10.1101/2020.05.27.20110601v1.full.pdf	RPCEC00000313	CIGB-258 immunomodulatory peptide	To determine the effect of Center for Genetic Engineering and Biotechnology (CIGB)-258 therapy in seriously, or critically ill patients with COVID-19.
02-juin	MedRxiv	A cohort study to evaluate the effect of combination Vitamin D, Magnesium and Vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients.	Observational study	Singapore	Chuen Wen Tan et al.	https://www.medrxiv.org/content/10.1101/2020.06.01.20112334v1.full.pdf	N/A	Vitamin D, Magnesium and Vitamin B12 (DMB)	To determine the clinical outcomes of older COVID-19 patients who received Vitamin D, Magnesium and Vitamin B12 (DMB) compared to those who did not
03-juin	MedRxiv	Therapeutic Anticoagulation Is Associated with Decreased Mortality in Mechanically Ventilated COVID-19 Patients	Retrospective analysis	USA	Trinh et al.	https://www.medrxiv.org/content/10.1101/2020.05.30.20117929v1.full.pdf	N/A	anticoagulation agents	To evaluate differences in morbidity and mortality among mechanically ventilated patients with COVID-19 treated with therapeutic versus prophylactic anticoagulation
05-juin	MedRxiv	Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial	CT	Italy	Perrone et al.	https://www.medrxiv.org/content/10.1101/2020.05.30.20119149v1.full.pdf	EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)	Tocilizumab	To evaluate efficacy of tocilizumab in COVID-19 pneumonia patients.
02/06/2020	MedRxiv	Rapid point of care nucleic acid testing for SARS-CoV-2 in hospitalised patients: a clinical trial and implementation study	prospective clinical trial and observational study	UK/South Africa	Dami Collier, et al.	https://www.medrxiv.org/content/10.1101/2020.05.31.20114520v1.full.pdf	NCT04326387	Nucleic acid diagnostic	To compare SAMBA II SARS-CoV-2 performance against the standard lab RTPCR test in suspected COVID-19 cases presenting to hospital, followed by a hospital-based implementation study.

06-juin	MedRxiv	Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity	Diagnostic comparison	Austria	Perkmann et al.	https://www.medrxiv.org/content/10.1101/2020.06.04.20117911v2.full.pdf	N/A	Antibody diagnostic	To compare three fully automated large-scale laboratory analyzer test systems, with particular emphasis on specificity, which is crucial for an adequate positive predictive value given the current low seroprevalence worldwide.
05-juin	MedRxiv	Implementation and evaluation of a novel real-time multiplex assay for SARS-CoV-2: In-field learnings from a clinical microbiology laboratory	Diagnostic validation study	Australia	Williams et al.	https://www.medrxiv.org/content/10.1101/2020.06.03.20117267v1.full.pdf	N/A	Nucleic acid diagnostic	To describe initial experience using a commercially-available multiplex two-step nested tandem RT-PCR assay for the detection of coronaviruses that infect humans, including SARS-CoV-2
02-juin	MedRxiv	Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay	Diagnostic validation study	USA/Switzerland	Danh et al.	https://www.medrxiv.org/content/10.1101/2020.05.28.20105692v1.full.pdf	N/A	Diagnostic for identifying suitable Convalescent plasma donors	To construct and validate a cell-free assay to measure neutralizing antibodies in order to identify suitable donors of convalescent plasma
02-juin	MedRxiv	Diagnostic accuracy of a host response point-of-care test for identifying COVID-19	diagnostic clinical evaluation	UK	Clark et al.	https://www.medrxiv.org/content/10.1101/2020.05.27.20114512v1.full.pdf	ISRCTN14966673	Diagnostic	To evaluate the real-world diagnostic accuracy of Febrifix for the identification of COVID-19 in hospitalised adults
August 2020	Journal of Clinical Virology	Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study	Diagnostic assay	Spain	García et al.	https://www.sciencedirect.com/science/article/pii/S1386653220302158?via%3DIhuh	NA	NA	To analyze the diagnostic performance of one serologic rapid test in COVID-19 patients
06-juin-20	Brain, Behaviour and Imunity	Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study	Retrospective study	China	Zhang et al.	https://www.sciencedirect.com/science/article/pii/S0889159120309946	NA	NA	Effects of sleep quality on recovery from lymphopenia and clinical outcomes in hospitalized patients with COVID-19
28 May 2020	Drug Safety	Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment	Systematic review	UK	Miranda Davies, et al.	https://doi.org/10.1007/s40264-020-00952-1	NA	Remdesivir	To assess the overall benefit-risk of the use of remdesivir as a treatment for COVID-19 compared with standard of care, placebo or other treatments

27 May 2020	Society of Critical Care	Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019	Observational study	USA	Thomas K. Maatman, et al.	DOI: 10.1097/CCM.0000000000004466	NA	Venous thromboembolism prophylaxis	To determine the frequency of venous thromboembolism (VT) in critically ill COVID19 patients who recieved prophylaxis for VT.
3 June 2020	JAMA	Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 - A Randomized Clinical Trial	RCT	China	Ling Li, et al.	doi:10.1001/jama.2020.10044	ChiCTR2000029757	Convalescent Plasma	Is convalescent plasma a safe and efficient treatment for severe COVID19?
Preprint	Journal of the American College of Cardiology	Ramipril in High Risk Patients with COVID-19	Retrospective analysis	Spain	Ignacio J. Amat-Santos, et al.	https://www.sciencedirect.com/science/article/pii/S073510972035395X?via%3DIihub	NCT03201185 (source RCT)	Ramipril	To analyze if ramipril modifies the risk for COVID-19.
3 June 2020	PlosOne	The need of health policy perspective to protect Healthcare Workers during COVID-19 pandemic. A GRADE rapid review on the N95 respirators effectiveness	Systematic review / Meta-analysis	Italy	Primiano Iannone, et al.	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0234025	NA	N95 respirators	Should health care workers wear surgical masks or N95 respirators during the routine care (not involving aerosol generating procedures) of COVID-19 suspected or affected patients?
1 June 2020	Lancet	Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis	Systematic review	International collaboration	Derek K Chu, et al.	https://doi.org/10.1016/S0140-6736(20)31183-1	PROSPERO: CRD42020177047	PPE	Investigate the effects of physical distance, face masks, and eye protection on virus transmission in health-care and non-health-care (eg, community) settings

Preprint	Diabetes, obesity & metabolism	Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case-control study	Case population study	Italy	Gian Paolo Fadini, et al.	https://pubmed.ncbi.nlm.nih.gov/32463179/	NA	DPP-4 inhibitors	Do DPP-4 inhibitors have a protective effect against COVID-19?
03 June 2020	NEJM	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19	RCT	USA / Canada	D.R. Boulware, et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2016638	NCT04308668.	Hydroxychloroquine	Is hydroxychloroquine effective in post-exposure prophylaxis therapy?
Preprint	Biosensors and Bioelectronics	Ultra-sensitive and high-throughput CRISPR-Powered COVID-19 diagnosis	Diagnostic assay	USA	Zhen Huang, et al.	https://doi.org/10.1016/j.bios.2020.112316	NA	CRISPR RT-PCR	Can CRISPR technology simplify RT-PCR for SARS CoV2 and be effective for diagnosis?
Preprint	Gastroenterology	Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study	Retrospective study	USA	Daniel E. Freedberg, et al.	https://www.gastrojournal.org/article/S0016-5085(20)34706-5/fulltext	NA	Famotidine	Do COVID-19 patients taking famotidine have a lower risk of intubation and/or death?
27 May 2020	NEJM	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19	RCT	International collaboration / Gilead Sciences	Jason D. Goldman, et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2015301	NCT04292899	Remdesivir	Is a 5 day course of remdesivir as effective as a 10 course in treating moderately ill COVID-19 patients?

22 May 2020	NEJM	Remdesivir for the Treatment of Covid-19 — Preliminary Report	J.H. Beigel, et al.	International collaboration	J.H. Beigel, et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2007764	NCT04280705	Remdesivir	Is remdesivir an effective treatment for reducing time to recovery in COVID19 patients?
Preprint	Journal of Allergy and Clinical Immunology	Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial	RCT	China	Yang Cao, et al.	https://doi.org/10.1016/j.jaci.2020.05.019	ChiCTR-OPN-2000029580.	Ruxolitinib	To evaluate the efficacy and safety of ruxolitinib for patients with severe COVID19.
Preprint	Clinical Infectious Diseases	Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID 19 by restoration of lymphocytopenia and reversion of exhausted T cells	Retrospective study	China	Yueping Liu, et al.	https://pubmed.ncbi.nlm.nih.gov/32442287/	NA	Thymosin alpha	Is thymosin alpha a safe and effective treatment for severe COVID19?
Preprint	International Journal of Infectious Diseases	HUMAN CORONAVIRUS DATA FROM FOUR CLINICAL TRIALS OF MASKS AND RESPIRATORS	Review	Australia	C Raina MacIntyre, et al.	https://www.sciencedirect.com/science/article/pii/S1201971220303994	NA	PPE	Level of protection conferred by masks and respirators for common coronavirus.
29-mai-20	The Lancet Rheumatology	Anakinra for severe forms of COVID-19: a cohort study	Cohort study	France	Huet et al.	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30164-8/fulltext	NA	Anakinra	Use of anakinra in patients who were admitted to hospital for severe forms of COVID-19

22-mai-20	The Lancet	Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial	CT	China	Feng-Cai Zhu et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext	NCT04313127	Ad5 vectored COVID-19 vaccine	Are different doses of Ad5 vectored COVID-19 vaccine safe and immunogenic?
29-mai-20	Preprint	A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danopevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19	Comparative study	China	Zhicheng Zhang et al.	https://www.researchsquare.com/article/rs-28376/v1.pdf	NA	Danopevir and lopinavir/ritonavir	Antiviral effect of danopevir or lopinavir/ritonavir in COVID-19 patients
01-juin-20	Current Medical Science	Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission—A Preliminary Report of a Retrospective Cohort Study	Observational study	China	Zhang et al.	https://link.springer.com/content/pdf/10.1007/s11596-020-2203-3.pdf	NA	Arbidol	Is Arbidol effective in prophylaxis of COVID?
26-mai-20	Advanced Journal of Emergency Medicine	Interferon beta-1a as a Candidate for COVID-19 Treatment; An Open-label Single-Arm Clinical Trial	CT	Iran	Payandemehr et al.	http://ajem.tums.ac.ir/index.php/ajem/article/view/454/307	IRCT20150914024017N1	Interferon beta1a	Is interferon beta1a effective in treatment of COVID-19?
13 July 2020	Antiviral Agents	Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial	RCT	Iran	Davoudi-Monfared et al.	https://aac.asm.org/content/early/2020/07/08/AAC.01061-20	IRCT20100228003449N28	Interferon beta-1a	To evaluate efficacy and safety of IFN β-1a in patients with severe COVID-19.
30/05/2020	medRxiv	A serological assay to detect SARS-CoV-2 antibodies in at-home collected fingerprick dried blood spots	Clinical Evaluation of diagnostic test	USA	Karp et al.	https://www.medrxiv.org/content/10.1101/2020.05.24.20116004v2.full.pdf	IRB protocol #20180015	Antibody diagnostic test	To develop and clinically evaluate an at-home finger-prick dried blood spot test to detect SARS-CoV-2 antibodies
27/05/2020	medRxiv	Performance evaluation of the point-of-care SAMBA II SARS-CoV-2 Test for detection of SARS-CoV-2	Clinical Evaluation of diagnostic test	UK/USA/South Africa	Assennato et al.	https://www.medrxiv.org/content/10.1101/2020.05.30.20100990v2.article-info	N/A	Nucleic acid diagnostic test	To assess the analytical and clinical performance of the SAMBA II 83 SARS-CoV-2 Test using panels and clinical samples.
30/05/2020	medRxiv	EasyCOV : LAMP based rapid detection of SARS-CoV-2 in saliva	Clinical Evaluation of diagnostic test	France	L'Helgouach et al.	https://www.medrxiv.org/content/10.1101/2020.05.30.20117291v1.full.pdf	N/A	saliva RT-LAMP diagnostic test	To develop and clinically evaluate a new simple saliva SARS-CoV-2 detection test based on RT-LAMP technology
27/05/2020	medRxiv	Evaluation of performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM-IgG Combined Antibody Tests	Clinical Evaluation of diagnostic test	France	Prazuck et al.	https://www.medrxiv.org/content/10.1101/2020.05.27.20112888v1.full.pdf	N/A	Antibody rapid diagnostic test	To evaluate the performance of two COVID 19 IgM/IgG Rapid Diagnostic Tests compared to the gold standard, RT-PCR.
29/05/2020	medRxiv	Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial	proof of concept study	Italy	Perotti et al.	https://www.medrxiv.org/content/10.1101/2020.05.26.20113373v1.full.pdf	NCT 04321421	convalescent plasma	To show the potential efficacy and safety of hyperimmune plasma infusions, obtained from convalescent donors, in COVID-19 patients with respiratory failure

26/05/2020	medRxiv	Use of High Flow Nasal Therapy to Treat Moderate to Severe Hypoxemic Respiratory Failure in COVID-19	Retrospective analysis	USA	Patel et al.	https://www.medrxiv.org/content/10.1101/2020.05.22.20109355v1.full.pdf		High Flow Nasal Therapy	To analyse the outcomes of COVID-19 patients with moderate-to-severe hypoxemic respiratory failure receiving High Flow Nasal Therapy
22-mai-20	The Lancet	Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	Observational study	USA/Switzerland	Mehra et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext	NA	Hydroxychloroquine	Are these treatment regimens associated with in-hospital death?
15 May 2020	Frontiers in Immunology	Interferon-a2b Treatment for COVID-19	CT	Canada, China	Qiong Zhou, et al.	https://www.frontiersin.org/articles/10.3389/fimmu.2020.01061/full	NA	Interferon-a2b	Is Interferon-a2b efficient in accelerating viral clearance and reducing inflammation markers?
19 May 2020	Clinical Infectious Diseases	Early Short Course Corticosteroids in Hospitalized Patients with COVID-19	Retrospective study	USA	Fadel et al.	https://www.medrxiv.org/content/10.1101/2020.05.04.20074609v1.full.pdf	NCT04374071	corticosteroids	To examine the role of early corticosteroid therapy in patients with moderate to severe COVID-19.
Preprint	medRxiv	Convalescent plasma treatment of severe COVID-19: A matched control study	CT	USA	Sean T. H. Liu, et al.	https://www.medrxiv.org/content/10.1101/2020.05.20.20102236v1	NA	Convalescent plasma	Is convalescent plasma an effective treatment for severe COVID19?

14 May 2020	Lancet	Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study	Case population study	Spain	Francisco J de Abajo, et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31030-8/fulltext	EUPAS34437	renin-angiotensin-aldosterone system inhibitors, RAAS	Does use of RAAS predispose patients to severe COVID19?
Preprint	Cardiology Journal	Resuscitation of the patient with suspected/confirmed COVID-19 when wearing personal protective equipment: A randomized multicenter crossover simulation trial	Randomized crossover trial	Poland	Marek Malysz, et al.	https://journals.viamedica.pl/cardiology_journal/article/view/68336	NA	PPE	To evaluate various methods of chest compressions in patients with suspected/confirmed SARS-CoV-2 infection conducted by medical students wearing full personal protective equipment (PPE) for aerosol generating procedures (AGP).
15 May 2020	NEJM	Compassionate Use of Remdesivir in Covid-19 (Grein et al. - NEMJ)	Letters to the editor	International	Stefano Bonovas, Gerd Fätkenheuer, Christian Hoffman, Jiayuan Wu	https://www.nejm.org/doi/full/10.1056/NEJMc2015312	NA	Remdesivir	Re-analysis of cumulative incidence of improvement, patient classification
Preprint	Clinical Microbiology and Infection	A multiple center clinical evaluation of an ultra-fast single-tube assay for SARS-CoV-2 RNA	Diagnostic clinical evaluation	China	Ji Wang, et al.	https://www.clinicalmicrobiologyandinfection.com/action/showPdf?pii=S1198-743X%2820%2930284-6	NA	Diagnostic test	To evaluate the performance of an ultra-fast single-tube nucleic acid isothermal amplification detection assay for SARS-CoV-2 RNA
Preprint	Journal of Clinical Virology	A combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2	Diagnostic assay comparison	Canada	Jason J., et al.	https://www.sciencedirect.com/science/article/pii/S1386653220301840	NA	Oropharyngeal/nares and nasopharyngeal swabs	Are combined oropharyngeal/nares swab is a suitable alternative for nasopharyngeal swabs for COVID19 sample collection?

19 May 2020	Nature	Artificial intelligence-enabled rapid diagnosis of patients with COVID-19	Diagnostic assay	China	Xueyan Mei, et al.	https://www.nature.com/articles/s41591-020-0931-3	N/A	AI diagnostic algorithm	Can an AI model rapidly identify SARS-CoV-2 infection based on initial chest CT scans and associated clinical information of COVID-19 (+) patients in the early stage?
23-mai	Medrxiv	Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19	retrospective analysis	South Korea	Sang Youl Rhee et al.	https://www.medrxiv.org/content/10.1101/2020.05.20.20108555v1.full.pdf	N/A	dipeptidyl peptidase-4 (DPP-4), renin-angiotensin system (RAS) blockade	To investigate the effects of dipeptidyl peptidase-4 (DPP-4) and renin-angiotensin system (RAS) blockade on the short-term clinical outcomes of COVID-19
22-mai	Medrxiv	Do COVID-19 patients admitted to the ICU require anti-Pneumocystis jirovecii prophylaxis?	prospective cohort study	France	Alanio	https://www.medrxiv.org/content/10.1101/2020.05.18.20105296v1.full.pdf	N/A	anti-Pneumocystis jirovecii prophylaxis	To investigate the prevalence of Pneumocystis jirovecii in COVID-19 patients admitted to the ICU
23/05/2020	Medrxiv	Development and clinical application of a rapid and sensitive loop-mediated isothermal amplification test for SARS-CoV-2 infection	Diagnostic	China	Hu et al.	https://www.medrxiv.org/content/10.1101/2020.05.20.20108530v2	N/A	RT-LAMP Diagnostic test	To develop and validate a novel RT-LAMP assay capable of detecting SARS-CoV-2 RNA for potential use in centralized facilities and point-of-care settings
22 May 2020	Medrxiv	Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support	retrospective analysis	Italy, UK	Gritti et al.	https://www.medrxiv.org/content/10.1101/2020.04.01.20048561v3.full.pdf	NCT04322188	siltuximab	Efficacy of siltuximab for treatment of severe patients with COVID-19
22-mai	Medrxiv	Almitrine as a non ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients	Case control series	France	Lossier et al.	https://www.medrxiv.org/content/10.1101/2020.05.18.20105502v1.full.pdf	N/A	Almitrine	To test if intravenous almitrine can improve hypoxia in mechanically ventilated COVID-19 patients.
12-mai	MedRxiv	Remdesivir in treatment of COVID-19: A systematic benefit-risk assessment	Systematic benefit-risk assessment	UK	Davies et al.	https://www.medrxiv.org/content/10.1101/2020.05.07.20093898v1.full.pdf	N/A	Remdesivir	To examine the benefit-risk profile of remdesivir in COVID-19 patients compared to standard of care, placebo or other treatments.

15-mai	MedRxiv	Assisting Scalable Diagnosis Automatically via CT Images in the Combat against COVID-19	Application of deep learning to retrospective analysis	China	Liu et al.	https://www.medrxiv.org/content/10.1101/2020.05.11.20093732v1.full.pdf	N/A	Chest CT	To test the hypothesis that application of deep learning to 3D chest CT images could help identify COVID-19 infections.
15-mai	MedRxiv	The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents	retrospective analysis	Belgium	De Spiegeleer et al.	https://www.medrxiv.org/content/10.1101/2020.05.11.20096347v1.full.pdf	N/A	ARBs, ACEi, Statins	To explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19 infected older people residing in nursing homes.
14-mai	MedRxiv	Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients	expanded access program	USA	Joyner et al.	https://www.medrxiv.org/content/10.1101/2020.05.12.20099879v1.full.pdf	NCT04338360	Convalescent plasma	To analyse key safety metrics following transfusion of convalescent plasma in patients with severe or life-threatening COVID-19
15-mai	MedRxiv	Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series	retrospective case study	USA	Weber et al.	https://www.medrxiv.org/content/10.1101/2020.05.13.20087734v1.full.pdf	NCT04387786	Nebulized in-line endotracheal Dornase Alfa	To report the clinical course, safety, and outcomes after nebulized in-line endotracheal dornase alfa treatment for intubated and mechanically ventilated patients with COVID-19.
13-mai	MedRxiv	Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas	Case series	USA	Salazar et al.	https://www.medrxiv.org/content/10.1101/2020.05.08.20095471v1.full.pdf	N/A	Convalescent plasma	To determine if transfusion of convalescent plasma is a safe treatment option for those with severe COVID-19 disease.
30 April 2020	Journal of Virus Eradication	A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?	Systematic review	UK	Victoria Pilkington, et al.	http://viruseradication.com/journal-details/A_review_of_the_safety_of_favipiravir_%E2%80%93_a_potential_treatment_in_the_COVID-19_pandemic%SE/	NA	Favipiravir	Safety of favipiravir
12 May 2020	Basic Research in Cardiology	Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series	Case series	USA	Siddharth Singh, et al.	https://link.springer.com/article/10.1007/s00395-020-0795-1	NA	CAP-1002	To evaluate the safety and impact of administration of allogeneic CDCs, formulated for intravenous (IV) infusion as CAP-1002, in critically ill COVID-19 patients.

Preprint	Canadian Medical Association Journal	Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis	Systematic Review ; Meta-analysis	International Collaboration	Zhikang Ye, et al.	https://www.cmaj.ca/content/cmaj/early/2020/05/14/cmaj.200645.full.pdf	NA	Corticosteroids	Assess efficacy and safety of corticosteroids for COVID19, SARS, MERS, CAP, ARDS and influenza
1 May 2020	Clinical and Experimental Rheumatology	Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19	CT	Italy	S. Sciascia, et al.	https://www.clinexprheumatol.org/abstract.asp?a=15723	NA	Tocilizumab	To assess the efficacy and safety of tocilizumab in severe COVID19 patients
23 April 2020	BMJ Global Health	Facial protection for healthcare workers during pandemics: a scoping review	Scoping Review	USA	Laura R Garcia Godoy, et al.	https://gh.bmj.com/content/5/5/e002553	NA	Facial protection	Efficacy of different facial protection devices, especially in light of N95 respirator shortages
Preprint	Pharmacological Research	Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post treatment hospitalisation status	Case series	Italy	Spinello Antinori, et al.	https://pubmed.ncbi.nlm.nih.gov/32407959/	NA	Remdesivir	Comparative efficacy of remdesivir in ICU and non-ICU patients
15 April 2020	Cochrane Library	Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff	Systematic Review	International Collaboration	Verbeek JH, et al.	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011621.pub4/full	NA	PPE	To evaluate which type of full-body PPE and which method of donning or do.ing PPE have the least risk of contamination or infection for HCW, and which training methods increase compliance with PPE protocols.
14 May 2020	Cochrane Library	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review	Systematic Review	Netherlands	Valk SJ, et al.	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600/full	NA	Convalescent Plasma	To assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID-19.

Preprint	Journal of Allergy and Clinical Immunology	Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease	Case series	Italy	Emanuele Pontali, et al.	https://www.jacionline.org/article/S0091-6749(20)30634-5/fulltext	NA	Anakinra	Preliminary assessment of the safety and efficacy of anakinra in severe/moderate COVID19
09 May 2020	Microorganisms	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results From SMAtteo COvid19 REgistry (SMACORE)	Observational study	Italy	Colaneri et al.	https://pubmed.ncbi.nlm.nih.gov/32397399/	NA	tocilizumab	What is the role of tocilizumab therapy in severe COVID-19 patients?
14 May 2020	BMJ	Hydroxychloroquine in Patients With Mainly Mild to Moderate Coronavirus Disease 2019: Open Label, Randomised Controlled Trial	RCT	China	Tang et al.	https://www.bmj.com/content/369/bmj.m1849.0	ChiCTR2000029868	Hydroxychloroquine	Is hydroxychloroquine effective and safe in COVID-19 patients?
05 May 2020	BMJ	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data	Observational study	France	Mahévas et al.	https://www.bmj.com/content/369/bmj.m1844	NA	Hydroxychloroquine	Is hydroxychloroquine effective?
08 May 2020	MedRxiv	Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients	Clinical Evaluation of diagnostic test	France	Tuillon et al.	https://www.medrxiv.org/content/10.1101/2020.05.04.20090027v3.full.pdf	NCT04347850	Antibody diagnostic test	To assess and compare the performance of 6 rapid tests and 3 ELISAs for the diagnosis of COVID-19, and to explore seroconversions in subjects with confirmed COVID-19
08 May 2020	MedRxiv	ddPCR: a more sensitive and accurate tool for SARS-CoV-2 detection in low viral load specimens	Clinical evaluation of diagnostic test	China	Suo et al.	https://www.medrxiv.org/content/10.1101/2020.02.29.20029439v2.full.pdf		PCR diagnostic test	To compare the dynamic range and the limit of detection (LoD) between ddPCR and RT-PCR
05 May 2020	MedRxiv	Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized, Controlled Trial	RCT	China	Yan Lou et al.	https://www.medrxiv.org/content/10.1101/2020.04.29.20085761v1.full.pdf	ChiCTR2000029544	baloxavir marboxil, favipiravir	To evaluate the efficacy and safety of adding baloxavir marboxil or favipiravir to the current standard antiviral treatment

11 May 2020	MedRxiv	Celebrex adjuvant therapy on COVID-19: An experimental study	Clinical trial	China	Wenxin Hong et al.	https://www.medrxiv.org/content/10.1101/2020.05.05.20077610v1.full.pdf	ChiCTR2000031630	Celebrex (Celecoxib)	To determine if excessive PGE2 may be a key in the pathology of COVID-19 and whether COX-2 is a critical target for therapy.
05 May 2020	MedRxiv	COVID-19 Related Mortality: Is the BCG Vaccine Truly Effective?	retrospective analysis of International mortality rates	Mexico	Paredes et al.	https://www.medrxiv.org/content/10.1101/2020.05.01.20087411v1.full.pdf	N/A	BCG	To take into account the possible confounders when analyzing the difference in mortality rates between countries with and without history of a universal BCG vaccination program.
08 May 2020	MedRxiv	Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients	retrospective observational study	USA	Carlucci et al.	https://www.medrxiv.org/content/10.1101/2020.05.02.20080036v1.full.pdf	N/A	zinc sulfate (as add-on therapy to hydroxychloroquine and azithromycin)	To determine if zinc sulfate added to hydroxychloroquine and azithromycin may improve outcomes among hospitalized patients.
05 May 2020	MedRxiv	Efficacy of face mask in preventing respiratory virus transmission: a systematic review and meta-analysis	Systematic review and meta-analysis	China	Liang et al.	https://www.medrxiv.org/content/10.1101/2020.04.03.20051649v3.full.pdf	N/A	facemask	To evaluate the effectiveness of the use of masks to prevent laboratory-confirmed respiratory virus transmission.
5 May 2020	Nature	Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis	Meta-analysis	China	Huan Li, et al.	https://www.nature.com/articles/s41375-020-0848-3.pdf	NA	Corticosteroids	Evaluate the safety and efficacy of corticosteroids on SARS-CoV-2, SARS-CoV, and MERS-CoV infections
Preprint	Journal of Biomedical and Health Informatics	In Silico Trial to test COVID-19 candidate vaccines: a case study with UISS platform		Italy	Giulia Russo, et al.	https://www.biorxiv.org/content/10.1101/2020.05.06.080630v1.full.pdf	NA	Vaccine	Can an efficient in-silico trial base be developed, and can it evaluate vaccine candidates?
Preprint	Nature	Effect of non-pharmaceutical interventions to contain COVID-19 in China	Mathematical Modeling	China, UK, US	Shengjie Lai, et al.	https://www.nature.com/articles/s41586-020-2293-x_reference.pdf	NA	Non-pharmaceutical interventions	Were non-pharmaceutical interventions effective in reducing the number of cases and speed of the epidemic in mainland China?
29 April 2020	Autoimmunity Reviews	Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis	Retrospective analysis	Israel	Omer Gendelman, et al.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198406/	NA	Colchicine, hydroxychloroquine	Protective role of colchicine or hydroxychloroquine for COVID19 infection

Preprint	Autoimmunity Reviews	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy	Observational study	Italy	Paola Toniati, et al.	https://www.sciencedirect.com/science/article/abs/pii/S1568997220301300	NA	Tocilizumab	Is tocilizumab effective for improving respiratory condition in severe COVID19?
April 29 2020	PNAS	Effective treatment of severe COVID-19 patients with tocilizumab	Retrospective analysis	China	Xiaoling Xua, et al.	https://www.pnas.org/content/pnas/early/2020/04/27/2005615117.full.pdf		Tocilizumab	Efficacy and safety of tocilizumab in sever COVID19
08 May 2020	The Lancet	Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial	RCT	Hong Kong	Hung et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext	NCT04276688	interferon beta-1b, lopinavir–ritonavir, ribavirin	The efficacy and safety of combination
07 May 2020	The Lancet Rheumatology	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study	Observational study	Italy	Cavalli et al.	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30127-2/fulltext	NCT04318366	anakinra	Efficacy of anakinra
19 April 2020	Journal of Clinical Virology	Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review	Systematic Review	USA	Alzghari et al.	https://www.sciencedirect.com/science/article/pii/S1386653220301220?via%3Dihub	NA	NA	Outcomes associated with TCZ treatment in patients with COVID-19
25 April 2020	Microbiology and Infection	Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study	Retrospective CT	China	N. Lian, et al.	https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30234-2/fulltext	NA	Umifenovir (Arbidol)	Effectiveness and safety of umifenovir for moderate COVID-19
16 April 2020	Journal of Infection	Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact	CT	Italy	Fabrizio Cantini, et al.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177073/	NA	Baricitinib	Is Baricitinib an effective drug for clinical and respiratory improvement in moderate COVID19 patients?
04 May 2020	medRxiv	Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19	growth curve analysis	USA	Berg et al.	https://www.medrxiv.org/content/10.1101/2020.04.05.20054163v5.full.pdf	N/A	BCG vaccination	Does BCG vaccination serve as a protective factor against COVID-19

22 April 2020	medRxiv	Does TB Vaccination Reduce COVID-19 Infection? No Evidence from a Regression Discontinuity Analysis	regression analysis based on observational data	USA/ Japan	Fukui et al.	https://www.medrxiv.org/content/10.1101/2020.04.13.20064287v1.full.pdf	N/A	BCG vaccination	To assess the effectiveness of BCG vaccination against COVID-19
29 April 2020	medRxiv	A Novel Protein Drug, Novaferon, as the Potential Antiviral Drug for COVID-19	RCT	China	Fang Zheng et al.	https://www.medrxiv.org/content/10.1101/2020.04.24.2007735v1.full.pdf	ChiCTR2000029496	Novaferon, Lopinavir/Ritonavir	To determine the antiviral effects of Novaferon for COVID-19
01 May 2020	medRxiv	Review and methodological analysis of trials currently testing treatment and prevention options for the novel coronavirus disease (COVID-19) globally.	Systematic review	Greece, France	Fragkou et al.	https://www.medrxiv.org/content/10.1101/2020.04.27.20080226v1.full.pdf	N/A	all treatment and preparation options for covid-19	To summarise the data on all currently tested treatment and prevention options for COVID-19, and to methodologically analyse and evaluate the quality of the registered interventional studies
01 May 2020	medRxiv	Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19	retrospective analysis	China	Bo Yu et al.	https://www.medrxiv.org/content/10.1101/2020.04.27.20073379v1.full.pdf	N/A	Hydroxychloroquine	Could hydroxychloroquine administration be beneficial in the treatment of critically ill patients with COVID-19?
29 April 2020	medRxiv	Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19	retrospective analysis	USA	Ip et al.	https://www.medrxiv.org/content/10.1101/2020.04.24.20077388v1.full.pdf	N/A	anti-hypertensive agents	To determine if anti-hypertensive drugs are harmful or beneficial to Covid-19 patients with hypertension
29 April 2020	medRxiv	Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study	retrospective analysis	China	Xiu Lan et al.	https://www.medrxiv.org/content/10.1101/2020.04.25.20079079v1.full.pdf	N/A	lopinavir/ritonavir, arbidol	To evaluate the antiviral efficacy of lopinavir/ritonavir alone or combined with arbidol in the treatment of hospitalized patients with COVID-19.
04 May 2020	medRxiv	Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19	prospective observational study	China	Mingxing Huang et al.	https://www.medrxiv.org/content/10.1101/2020.04.26.20081059v1.full.pdf	ChiCTR200002960	Chloroquine	To assess the efficacy and safety of chloroquine with different doses in COVID-19
01 May 2020	medRxiv	QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin	retrospective analysis	USA/Italy	Chorin et al.	https://www.medrxiv.org/content/10.1101/2020.04.27.20074583v1.full.pdf	N/A	Hydroxychloroquine, Azithromycin	To evaluate the effects of Hydroxychloroquine/Azithromycin on the QT interval and the arrhythmic risk in patients with SARS-CoV-2 infection.
01 May 2020	medRxiv	Performance & Quality Evaluation of Marketed COVID-19 RNA Detection Kits	diagnostic kit evaluation	China	David Surace Kapitula et al.	https://www.medrxiv.org/content/10.1101/2020.04.25.20080002v1.full.pdf	N/A	qPCR Diagnostic test	To assess and compare all nucleic acid-based COVID-19 testing kits from quality control perspectives

29 April 2020	medRxiv	Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review	Systematic review	USA/Canada	Michaud et al.	https://www.medrxiv.org/content/10.1101/2020.04.21.20066761v2.full.pdf	N/A	azithromycin, chloroquine, favipiravir, lopinavir/ritonavir, remdesivir	To determine the relative risk of drug-induced Long QT Syndrome (LQTS) associated with SARS-CoV-2 (COVID-19) proposed repurposed drugs compared to well-known torsadogenic compounds
29 April 2020	medRxiv	Concentration-dependent mortality of chloroquine in overdose	retrospective analysis, Bayesian logistic regression, pharmacodynamic modelling	Thailand/UK/ France	Watson et al.	https://www.medrxiv.org/content/10.1101/2020.04.24.20078303v1.full.pdf	N/A	Chloroquine	To evaluate the risk of overdose for chloroquine treatment or prevention regimens currently being trialled in COVID19
29 April 2020	The Lancet	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial	RCT	China	Wang et al.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext	NCT04257656	remdesivir	Effect of remdesivir in COVID-19 patients
02 May 2020	Academic Emergency Medicine	A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.	Systematic review	USA	Chowdhury et al.	https://onlinelibrary.wiley.com/doi/abs/10.1111/acem.14005	NA	NA	Analyze current literature to find the role of CQ and HCQ
20 April 2020	medRxiv	Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A Multicenter Retrospective Cohort Study	retrospective cohort study	China	Ziyun Shao et al.	https://www.medrxiv.org/content/10.1101/2020.04.11.20061739v2.full.pdf	N/A	intravenous immunoglobulin (IVIg) therapy	To determine the clinical efficacy of intravenous immunoglobulin (IVIg) therapy in COVID-19 patients.
22 April 2020	Clin Pharmacol Ther.	Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation.	pharmacokinetic (PBPK) model	Netherlands	Verscheijden et al.	https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1864	N/A	Chloroquine	To establish best-evidence to inform pediatric Chloroquine doses for children infected with COVID-19
24 April 2020	JAMA Network Open	Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.	RCT	Brazil	Borba et al	https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499	NCT04323527	Chloroquine	To evaluate the safety & efficacy of different dosages of chloroquine in patients with severe COVID-19.
21 April 2020	medRxiv	A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α -Lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19)	RCT	China	Zhong et al.	https://www.medrxiv.org/content/10.1101/2020.04.15.20066266v1.full.pdf	ChiCTR2000029851	α -Lipoic acid (ALA)	To evaluate the clinical efficacy and safety of α -Lipoic acid (ALA) for critically ill patients with COVID-19.

22 April 2020	medRxiv	Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis	Rapid review and meta-analysis	China	Shuya Lu et al	https://www.medrxiv.org/content/10.1101/2020.04.17.20064469v1	N/A	Glucocorticoids	To systematically retrieve and summarize the current evidence of the effectiveness and safety of glucocorticoid therapy for patients with COVID-19
26 April 2020	MedRxiv	A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections	Systematic review	UK	Khan et al	https://www.medrxiv.org/content/10.1101/2020.04.23.20076612v1.full.pdf	N/A	Anakinra, Tocilizumab, Sarilumab, Siltuximab	To assess the effectiveness of specific interleukin-1 and -6 inhibitors for the treatment of coronavirus-related infections.
13 April 2020	Press release	Southern California Patients Treated with Leronlimab for COVID-19 under Emergency IND	Preliminary results from clinical trial	USA	CytoDyn INC.	https://www.cytodyn.com/newsroom/press-releases/detail/415/southern-california-patients-treated-with-leronlimab-for	NA	leronlimab	Could leronlimab be effective?
28 February 2020	Aging and Disease	Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia	CT	China	Leng et al.	http://dx.doi.org/10.14336/AD.2020.0228	ChiCTR2000029990	ACE2-mesenchymal stem cell	Efficacy of MSC transplantation in COVID patients
26 March 2020	Journal of Medical Virology	Tocilizumab treatment in COVID-19: a single center experience	Observational study	China	Luo et al.	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25801	NA	tocilizumab	What are treatment responses of TCZ in the COVID-19 patients?
17 April 2020	Circulation Research	Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19	Observational study	China	Zhang et al.	https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.317134	NA	Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs)	To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in COVID-19 patients with hypertension
23 April 2020	JAMA	Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China	Case series	China	Juy Li, et al	https://jamanetwork.com/journals/jamacardiology/fullarticle/2765049	NA	Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin receptor blockers (ARBs)	Asses the association between ACEIs/ARBs and severity of illness and mortality in patients with hypertension hospitalized for COVID-19 infection.
PrePrint	Acta Pharmaceutica Sinica B	Potential therapeutic effects of dipyrindamole in the severely ill patients with COVID-19	RCT	China	Xiaoyan Liu, et al.	https://www.sciencedirect.com/science/article/pii/S2211383520305529	NA	Dipyridamole	Is treatment with dipyrindamol clinically effective in severely ill COVID19 patients?

18 April 2020	medRxiv	Benefits and Risks of Chloroquine and Hydroxychloroquine in The Treatment of Viral Diseases: A Meta-Analysis of Placebo Randomized Controlled Trials	meta-analysis of RCTs	China/ USA	Jing Wang et al	https://www.medrxiv.org/content/10.1101/2020.04.13.20064295v1.full.pdf		chloroquine/hydroxychloroquine	To evaluate the efficacy and safety of Chloroquine and hydroxychloroquine
20 April 2020	medRxiv	Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 2 - Hand hygiene and other hygiene measures: systematic review and meta-analysis.	systematic review and meta-analysis	Saudi Arabia, Australia, Canada	Al-Ansary	https://www.medrxiv.org/content/10.1101/2020.04.14.20065250v1.full.pdf	NA	hygiene interventions	To assess the effectiveness of hand hygiene, surface disinfecting, and other hygiene interventions in preventing or reducing the spread of illnesses from respiratory viruses
17 April 2020	medRxiv	An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area	Clinical trial	China	Meng et al.	https://www.medrxiv.org/content/10.1101/2020.04.11.20061473v1.full.pdf	NCT04320238	Recombinant human interferon-alpha nasal drops	To investigate the efficacy and safety of recombinant human interferon alpha1b (rhIFN- α) nasal drops in healthy medical staff to prevent COVID-19.
23 March 2020, updated 15 April 2020	medRxiv	An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)	RCT	China	Li et al.	https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v2.full.pdf	NCT04252885	lopinavir/ritonavir (Kaletra), arbidol	Lopinavir-Ritonavir combination compared to Arbidol compared to no antiviral treatment
17 April 2020	medRxiv	Potential Effectiveness and Safety of Antiviral Agents in Children with Coronavirus Disease 2019: A Rapid Review and Meta-Analysis	review and meta-analysis	China	Shi et al.	https://www.medrxiv.org/content/10.1101/2020.04.13.20064436v1.full.pdf	NA	antivirals	To assess the potential effectiveness and safety of antiviral agents for COVID-19 in children.

17 April 2020	medRxiv	Efficacy and Safety of Antibiotic Agents in Children with COVID-19: A Rapid Review	rapid review	China	Wang et al	https://www.medrxiv.org/content/10.1101/2020.04.13.20064402v1.full.pdf	NA	antibiotics	The aim of this review was to evaluate the efficacy and safety of antibiotic agents in children with COVID-19
Preprint	Médecine et Maladies Infectieuses	No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection	Prospective virological assay	France	JM Molina et al.	https://www.sciencedirect.com/science/article/pii/S0399077203008587via%3Dihub	NA	Hydroxychloroquine, azithromycin	Is hydroxychloroquine effective for viral clearance when reproducing the study of Gautrel et al.?
Accepted 31 March 2020	Journal of Infection	The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis	Meta-analysis	China	Zhenwei Yang, et al.	https://www.sciencedirect.com/science/article/pii/S0399077203008587via%3Dihub	Grant from the National Natural Science Foundation of China (Jing Liu, grant no. 81472735) and the Wuhan University (Jing Liu, grant no. 2042019kf0206	Corticosteroids	Evaluate the influence of corticosteroids in patients with coronavirus.
Preprint	Clinical Infectious Diseases	Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients	Prospective PK study	France	Sophie Perinel et al,	https://academic.oup.com/jmcb/article/doi/10.1093/jmcb/ciaa394/5816960	NA	Hydroxychloroquine	What is the best dose of hydroxychloroquine for COVID19 patients?
	Journal of Molecular Cell Biology	Treating COVID-19 with Chloroquine	RCT	China	Mingxing Huang, et al.	https://academic.oup.com/jmcb/article/doi/10.1093/jmcb/mjaa014/5814655	NA	Chloroquine, lopinavir, ritonavir	Is chloroquine better than lopinavir/ritonavir in severe and moderate COVID19 patients?
10 April 2020	NEJM	Compassionate Use of Remdesivir for Patients with Severe Covid-19	Report	UK, Canada, Europe, Japan	Grein et al.	https://www.nejm.org/doi/full/10.1056/NEJMoa2007016	NA	Remdesivir	NA
10 March 2020	Journal of Critical Care	A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19	Systematic review	Italy	Andrea Cortegiani, et al.	https://www.sciencedirect.com/science/article/pii/S0883944120303907via%3Dihub	NA	Chloroquine	Summary of the existing the evidence on chloroquine for the treatment of COVID-19
Preprint	Journal International AIDS Society	Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID-19: initial assessment	Systematic review	Switzerland	N Ford et al.	https://onlinelibrary.wiley.com/doi/10.1002/jia2.25489	NA	Antiretroviral drugs	Systematic review of the clinical outcomes of using antiretroviral drugs for the prevention and treatment of coronaviruses and
30 March 2020	Complementary Therapies in Clinical Practice	Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study	Non-interventional RCT	China	Kai Liu, et al.	https://www.sciencedirect.com/science/article/pii/S1744388120304278	Ethics committees of Hainan General Hospital and Huanggang Central Hospital (approval numbers: 19758 and 20200125)	Respiratory rehabilitation training	Investigate the effects of 6-week respiratory rehabilitation training on respiratory function, QoL, mobility and psychological function in elderly patients with COVID-19

6 March 2020	Complementary Therapies in Clinical Practice	Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19	Non-interventional RCT	China	Kai Liu, et al.	https://www.sciencedirect.com/science/article/pii/S1744388120302784	NA	Progressive muscle relaxation (sleep therapy)	Investigate the effect of progressive muscle relaxation on anxiety and sleep quality of COVID-19 patients
24 March 2020	MedRxiv	First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients	CT	China	Chen et al.	https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1.full.pdf	NCT04291729	danoprevir/ritonavir	Effect of danoprevir in moderate COVID-19 patients
07 April 2020	MedRxiv	The potential of low molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a retrospective clinical study	Retrospective CT	China	Chen Shi et al.	https://www.medrxiv.org/content/10.1101/2020.03.28.20046144v2	not found	enoxaparin	Efficacy of enoxaparin
14 April 2020	MedRxiv	No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial	Retrospective analysis	France	Matthieu Mahévas et al.	https://www.medrxiv.org/content/10.1101/2020.04.10.20060699v1.full.pdf	NA	Hydroxychloroquine	To assess the effectiveness of Hydroxychloroquine in patients with severe Covid-19
27 March 2020	JAMA	Treatment of 5 critically ill patients with COVID-19 with convalescent plasma	Observational study	China	C Shen, et al.	https://jamanetwork.com/journals/jama/fullarticle/2763983	Grants: National Science and Technology Major Project (2018ZX10711001, 2017ZX10103011, 2017ZX10204401), Sanming Project of Medicine in Shenzhen (SZSM201412003, SZSM201512005), China Postdoctoral Science Foundation (2019T120147, 2018M641508), Shenzhen Science and Technology Research and Development	Convalescent plasma	Is plasma from convalescent patients beneficial for critically ill COVID19 patients?

6 April 2020	Proceedings of the National Academy of Sciences of the United States of America	The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study	Observational/retrospective control	China	Kai Duan et al	https://www.pnas.org/content/early/2020/04/02/2004168117	ChiCTR2000030048	Convalescent plasma	Is treatment with convalescent plasma safe and beneficial for COVID19 patients?
Preprint	Influenza and other Respiratory Viruses	Medical Masks vs N95 Respirators for Preventing COVID-19 in Health Care Workers - A Systematic Review and Meta-Analysis of Randomized Trials	Systematic review	Canada	Jessica J Bartoszko, et al.	https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12745	NA	N95 respirators vs surgical masks	Compare medical masks to N95 respirators in preventing laboratory confirmed viral infection and respiratory illness specifically in health care workers.
Preprint	Disaster Medicine and Public Health Preparedness	RANDOMIZED TRIAL OF INSTRUCTOR-LED TRAINING VERSUS VIDEO LESSON IN TRAINING HEALTH CARE PROVIDERS IN PROPER DONNING AND DOFFING OF PERSONAL PROTECTIVE EQUIPMENT	RCT	Denmark	L Christensen et al	https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/article/ randomized-trial-of-instructor-led-training-versus-video-lesson-in-training-health-care-providers-in-proper-doffing-and-doffing-of-personal-protective-equipment/CF08F4727DA9D536883ECBF048C2570	NA	Training on personal protective equipment	Is attending one live training session or watching video trainings over a month more effective for training on donning and doffing personal protective equipment?
Preprint	Journal of Medical Virology	Performance of VivaDiag™ COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department	Diagnostic assay	Italy	Irene Cassantini et al.	https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25800	NA	Diagnostic serological assay	To assess an easy to perform serological assay for diagnosis of COVID19
Preprint	Journal of Clinical Microbiology	Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2	Diagnostic assay	China	Wanbing Liu, et al.	https://jcm.asm.org/content/early/2020/03/27/10.1128/JCM.00461-20	DOI: 10.1128/JCM.00461-20; Hospital Ethics Committee of the General Hospital of the Central Theater Command 107 of the PLA ([2020]003-1)	Diagnostic serological assay	Evaluate the diagnostic feasibility of two ELISA assays
Article originally published in 2015; authors added comment on 30/03/2020	BMJ Open	A cluster randomised trial of cloth masks compared with medical masks in healthcare workers	RCT	Australia/Vietnam	MacIntyre CR et al.	https://bmjopen.bmj.com/content/5/4/e006577	Australian New Zealand Clinical Trials Registry: ACTRN12610000887077.	medical masks, cloth masks	To compare the efficacy of cloth masks to medical masks in hospital healthcare workers

31 March 2020	MedRxiv	Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial	RCT	China	Zhaowei Chen et al.	https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2	ChiCTR2000029559	Hydroxychloroquine	Assess the efficacy of hydroxychloroquine
Preprint		Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study	RCT	France	Gautret et al.	https://www.mediterranean-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf	NA	Hydroxychloroquine, Azithromycin	Assess the efficacy of hydroxychloroquine associated with azithromycin
23 March 2020 (preprint, not yet peer-reviewed)	BMJ	An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)	RCT	China	Li et al.	https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1	NCT04252885	lopinavir/ritonavir (Kaletra), arbidol	Lopinavir-Ritonavir combination compared to Arbidol compared to no antiviral treatment
10 Feb 2020	Biosci Trends	Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.	Summary of 15 CTs	China	Gao et al.	https://www.ijstage.istg.org/article/bst/14/1/14_2020.01047/_article	ChiCTR2000029939 , ChiCTR2000029935 , ChiCTR2000029899 , ChiCTR2000029898 , ChiCTR2000029868 , ChiCTR2000029837 , ChiCTR2000029826 , ChiCTR2000029803 , ChiCTR2000029762 , ChiCTR2000029761 , ChiCTR2000029760 , ChiCTR2000029740 , ChiCTR2000029609 , ChiCTR2000029559 and	Chloroquine	Could chloroquine be effective?
30 March 2020	not published yet	Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients	Preliminary results from clinical trial	USA	CytoDyn Inc.	https://www.cytodyn.com/newsroom/press-releases/detail/401/three-additional-patients-with-severe-covid-19-treated-with	NA	Leronlimab	Could leronlimab be effective?
27 March 2020	medRxiv	Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial	RCT	China	Chang Chen et al.	https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2	ChiCTR2000030254	Favipiravir, Arbidol	Conventional therapy + favipiravir or arbidol?

20 March 2020	International Journal of Antimicrobial Agents	Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial	CT	France	Gautret et al.	https://www.sciencedirect.com/science/article/pii/S0924857920300996#	EudraCT number 2020-000890-25	Hydroxychloroquine, Azithromycin	Role of hydroxychloroquine on respiratory viral loads
19 March 2020	N Engl J Med	A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.	RCT	China	Cao et al.	https://www.ncbi.nlm.nih.gov/pubmed/32187464	ChiCTR2000029308	lopinavir/ritonavir (Kaletra)	Lopinavir-Ritonavir combination compared to conventional therapy ?
11 March 2020	Journal of Infection	Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study	Retrospective cohort study	China	Lisi Deng	https://www.sciencedirect.com/science/article/pii/S0163444520301134?via%3Dihub	NA	Lopinavir/ritonavir, Arbidol	Arbidol and lopinavir-ritonavir compared to lopinavir-ritonavir only?
In press	British Journal of Anaesthesia	High-flow nasal-oxygenation- assisted fiberoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial	RCT	China	Cai-Neng Wu et al.	https://bjanaesthesia.org/article/S0007-0912(20)30135-5/fulltext	ChiCTR2000029658	High-flow nasal oxygenation	What is the efficacy and safety of high-flow nasal oxygenation during fiberoptic bronchoscopic intubation in critically ill patients with COVID-19?
2020 Pre-print online	Chinese Journal of Infectious Diseases,	Efficacy of lopinavir, ritonavir and Arbidol for the treatment of new coronavirus pneumonia	Retrospective analysis	China	Chen Jun et al.	http://rs.yijie.com/yufabiao/1182592.htm	NA	Lopinavir/ritonavir, Arbidol	Efficacy of lopinavir/ritonavir and arbidol
2020	Journal of Zhejiang University (Medical Science) 2020 , Vol. 49 Issue (1)	A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)	RCT	China	Chen Jun et al.	http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.03	NCT04261517	Hydroxychloroquine	Role of hydroxychloroquine on respiratory viral loads
2020 Pre-print	MedRxiv	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial	CT	China	Huijie Bian et al.	https://doi.org/10.1101/2020.03.21.20040691	NCT 04275245	Meplazumab	Assess the efficacy and safety of meplazumab, a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.